CHAPTER 7: Traditional Cytotoxic Agents as Antibody-Drug Conjugate (ADC) Payloads

Ilona Pysz, Paolo Andriollo, David E. Thurston*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Citation (Scopus)


Although the concept of antibody-drug conjugates (ADCs) appears simple, the development of successful and efficacious agents has proved challenging. For example, many parameters have to be optimized to create a successful ADC product, some of which are specific to individual tumour types and antibodies. Important parameters include ADC stability (e.g. the payload should not be released before the ADC reaches its target in vivo), pharmacokinetics (e.g. the payload should not lead to undesired accumulation in a non-target organ), retention of immuno-reactivity, and efficient release of the active form of the payload at the disease site. Early work on ADCs relied on clinically-approved chemotherapeutic drugs as payloads with the aim of increasing tumour specificity.

Original languageEnglish
Title of host publicationTherapies for Retinal Degeneration
Subtitle of host publicationTargeting Common Processes
EditorsDavid E. Thurston, Paul J. M. Jackson
PublisherRoyal Society of Chemistry
Number of pages29
Publication statusPublished - 1 Jan 2019

Publication series

NameRSC Drug Discovery Series
ISSN (Print)2041-3203
ISSN (Electronic)2041-3211


Dive into the research topics of 'CHAPTER 7: Traditional Cytotoxic Agents as Antibody-Drug Conjugate (ADC) Payloads'. Together they form a unique fingerprint.

Cite this